![5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II study - The Lancet Regional Health – Western Pacific 5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II study - The Lancet Regional Health – Western Pacific](https://www.thelancet.com/cms/attachment/3c7aba1b-3db6-4ff9-ab99-2372235ed45f/gr1.jpg)
5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II study - The Lancet Regional Health – Western Pacific
HIV-1 RNA Dysregulates the Natural TLR Response to Subclinical Endotoxemia in Kenyan Female Sex-Workers | PLOS ONE
![Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells - ScienceDirect Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S221112471730935X-fx1.jpg)
Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells - ScienceDirect
![Antiviral Activity, Safety and Pharmacokinetics of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance, in Treatment-Naïve HIV-1-Infected Subjects Antiviral Activity, Safety and Pharmacokinetics of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance, in Treatment-Naïve HIV-1-Infected Subjects](https://www.natap.org/2008/images/061208/Subjct-1.gif)